Broncho-Vaxom Adult, capsules 7 mg, 10 pcs.

Pharmacotherapeutic group

Immunostimulant.

TATX code: L03A.

Immunobiologic action

Broncho-Vaxom® Adult stimulates the body’s immune defense and increases resistance to respiratory system infections, Immuno pharmacologic studies have shown that Broncho-Vaxom® Adult has the following effects:

-increases the formation of immunoglobulin A (IgA) secreted by respiratory tract mucosa and saliva;
-increases the number of circulating T lymphocytes.

Clinically Broncho-Vaxom® adult reduces the frequency of acute respiratory tract infections, reduces the duration of their course, as well as reduces the likelihood of exacerbations of chronic bronchitis. At the same time, the need for other medications, especially antibiotics, is reduced.

Indications

Prevention of recurrent respiratory tract infection and exacerbations of chronic bronchitis. Use in the complex treatment of acute respiratory tract infections.

Active ingredient

Composition

Active substance:

OM-85 lyophilizate – 40.00 mg:

standardized bacterial lysates lyophilisate (Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridans, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis) – 7 mg;

Auxiliary substances:

Anhydrous propyl gallate (E 310) – 0.084 mg,

monosodium glutamate (corresponding to anhydrous sodium glutamate (sodium glutamate)) – 3.03 mg,

mannitol – the required amount up to 40.00 mg,

pregelatinized starch -110.00 mg,

Magnesium stearate – 3.00 mg,

Mannitol – required amount up to 200.00 mg;

The capsule shell excipients:

indigo carmine (indigotine) (dye E 132) – 0.03 mg, titanium dioxide (dye E 171) – 1.00 mg, gelatin – the required amount – up to 50.00 mg.

How to take, the dosage

For the treatment of acute and exacerbation of chronic respiratory infections: children over 12 years and adults should take one capsule Broncho-Vaxom daily on an empty stomach until the disappearance of symptoms, at least 10 days.

If antibiotic therapy is necessary, Broncho-Vaxom should be taken in combination with an antibiotic from the beginning of treatment. The duration of treatment should be determined by the doctor based on the individual condition of the patient.

For prevention of exacerbations and maintenance therapy: children over 12 years of age and adults should take one capsule of Broncho-Vaxom daily in the morning on an empty stomach.

The treatment course includes three cycles, each of which consists of the daily use of one capsule for 10 days, the interval between the cycles is 20 days. For children aged 6 months to 12 years who are prescribed the children’s form, the method of administration is identical. In case the child has difficulty swallowing the capsule, it should be opened and the contents mixed with a drink (fruit juice, milk, etc.)

.

Interaction

Broncho-Vaxom® Adult can be used simultaneously with other medicinal products for the treatment of acute and chronic respiratory diseases.

The drug interaction of Broncho-Vaxom® Adult with other medicinal products has not yet been established.

Special Instructions

There is no need to take precautions when using the drug.

Impact on driving and operating machinery

Broncho-Vaxom® Adult does not affect the ability to drive vehicles and operate machinery.

Contraindications

Hypersensitivity to the components of the drug.

On the basis of available information, it is not recommended to prescribe to children under 6 months of age due to the immaturity of their immune system.

In order to avoid overdose, children should not take the product from capsules intended for adults.

Side effects

Broncho-Vaxom® adult is usually well tolerated. The results of clinical studies indicate that the incidence of mild adverse reactions is 3-4%.

Digestive system disorders: nausea, abdominal pain, vomiting.

Dermatological reactions: itching, erythema.

Respiratory system: cough, shortness of breath.

Nervous system disorders: headache, feeling of fatigue.

In case of continuing gastrointestinal disorders, skin reactions and respiratory manifestations, the drug should be stopped, because they may be allergic reactions. In such a situation, the patient should consult with their physician.

Overdose

There are no reports of overdose. The nature of Broncho-Vaxom® adult and the results of its toxicity study indicate that overdose is unlikely.

Pregnancy use

Reproduction studies in animals have shown no danger to the fetus, but controlled studies in pregnant women have not been conducted. No specific studies have been performed on breastfeeding and no data on this subject are available to date.

The drug is contraindicated in children under 6 months of age.

Children between 6 months and 12 years of age should use Broncho-Vaxom for children.

Similarities